ATE294865T1 - Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance' - Google Patents

Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'

Info

Publication number
ATE294865T1
ATE294865T1 AT99904857T AT99904857T ATE294865T1 AT E294865 T1 ATE294865 T1 AT E294865T1 AT 99904857 T AT99904857 T AT 99904857T AT 99904857 T AT99904857 T AT 99904857T AT E294865 T1 ATE294865 T1 AT E294865T1
Authority
AT
Austria
Prior art keywords
staphylokinase
dna fragment
derivatives
identification
reduced
Prior art date
Application number
AT99904857T
Other languages
English (en)
Inventor
Desire Jose Collen
Original Assignee
Thromb X N V
Desire Jose Collen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thromb X N V, Desire Jose Collen filed Critical Thromb X N V
Application granted granted Critical
Publication of ATE294865T1 publication Critical patent/ATE294865T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99904857T 1998-02-04 1999-02-04 Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance' ATE294865T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98200323 1998-02-04
EP98200365 1998-02-06
PCT/EP1999/000748 WO1999040198A2 (en) 1998-02-04 1999-02-04 Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance

Publications (1)

Publication Number Publication Date
ATE294865T1 true ATE294865T1 (de) 2005-05-15

Family

ID=26150019

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99904857T ATE294865T1 (de) 1998-02-04 1999-02-04 Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'

Country Status (9)

Country Link
US (1) US20050136045A1 (de)
EP (1) EP1053330B1 (de)
JP (1) JP2002505082A (de)
CN (1) CN1322126C (de)
AT (1) ATE294865T1 (de)
AU (1) AU2521999A (de)
CA (1) CA2319693A1 (de)
DE (1) DE69925110T2 (de)
WO (1) WO1999040198A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028248T2 (de) * 1999-12-02 2007-03-15 Thromb-X N.V. Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
CN100342007C (zh) * 2000-01-28 2007-10-10 复旦大学 一种新型重组葡激酶及其制备方法
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
AU2002327310B2 (en) 2001-07-17 2006-09-28 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN100445389C (zh) * 2005-10-14 2008-12-24 中国人民解放军军事医学科学院基础医学研究所 一种低抗原性重组葡激酶突变体及制备方法
CN100445390C (zh) * 2005-10-14 2008-12-24 中国人民解放军军事医学科学院基础医学研究所 一种高活性、低抗原性葡激酶衍生体及制备方法
CN101112358B (zh) * 2006-07-26 2011-04-20 中国科学院上海生命科学研究院 葡激酶肌肉注射剂及其制备方法
TR201001630T1 (tr) * 2007-10-09 2010-05-21 Thrombogenics N.V. Stafilokinaz varyantı.
CN102451471B (zh) * 2010-10-14 2013-10-16 中国科学院过程工程研究所 聚乙二醇-葡激酶偶联物及其制备方法和应用
CN102212512B (zh) * 2011-04-22 2015-10-21 河北师范大学 一种聚乙二醇化的葡激酶突变体及其制备方法和应用
CN104293762A (zh) * 2014-09-30 2015-01-21 河北师范大学 聚乙二醇-葡激酶突变体偶联物的制备及纯化方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147989T1 (de) * 1991-06-28 1997-02-15 Leuven Res & Dev Vzw Verwendung von staphylokinase für die herstellung einer zusammensetzung für die behandlung von gefässthrombose
DE59206628D1 (en) * 1991-12-30 1996-07-25 Medac Klinische Spezialpraep Expression signalpeptid-freier staphylokinasen
EP0721982A1 (de) * 1995-01-06 1996-07-17 Leuven Research & Development V.Z.W. Neue staphylokinase Derivative

Also Published As

Publication number Publication date
EP1053330A2 (de) 2000-11-22
WO1999040198A2 (en) 1999-08-12
EP1053330B1 (de) 2005-05-04
DE69925110D1 (de) 2005-06-09
AU2521999A (en) 1999-08-23
CA2319693A1 (en) 1999-08-12
US20050136045A1 (en) 2005-06-23
CN1322126C (zh) 2007-06-20
CN1293712A (zh) 2001-05-02
DE69925110T2 (de) 2006-02-02
JP2002505082A (ja) 2002-02-19
WO1999040198A3 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
ATE294865T1 (de) Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
DE3851225D1 (de) Blutersatz.
CY1116110T1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
BE2014C077I2 (de)
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
IL86693A0 (en) Novel proteins with factor viii activity,process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DK1274728T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
EP0434713A4 (en) Hiv-1 envelope muteins lacking hypervariable domains
ES8800347A1 (es) Metodo para preparar uroquinasa de una sola cadena resistente a proteasas
ATE103982T1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
MY104910A (en) New derivatives of human/bovine4 basic fibroblast growth factor.
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
KR900701832A (ko) 항-트롬빈
ES8704184A1 (es) Un metodo para producir un polipeptidos similar a lipocortina humana.
HK1007333A1 (en) Variants of plasminogen activatos and processes for their production
HUP9901161A2 (hu) Módosított aktivitású hibrid VIII. faktor
IL165808A0 (en) Low molecular weight k5-n,o-oversulfated polysaccharide process for the preparation thereof and pharmaceutical compositions containing the same
ATE139568T1 (de) Achromobacter-protease-i-gen sowie genprodukt
DK0496866T3 (da) Hæmoglobin-oligomerbaseret præparat og fremgangsmåde til fremstilling deraf
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DK161738C (da) Fremgangsmaade til indblanding af et laegemiddel i et rygeligt tobaksprodukt
EP1126858A4 (de) Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen
UA31379A (uk) Спосіб лікування ішемічної хвороби серця
DE04000874T1 (de) Menschliches therapeutisches Albumin mit niedriger Aluminiumbindungsfähigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties